Metagenomi Therapeutics announces FDA clearance for MGX-001 and reports third-quarter 2026 results
MGX•Metagenomi Therapeutics announced FDA clearance of its investigational new drug application for MGX-001 and reported third-quarter 2026 financial results. It plans to initiate the INTEGR8 trial in the first half of 2027, with initial data expected in the second half of 2027.
1. Trial plans
Metagenomi Therapeutics said it plans to initiate the INTEGR8 trial in the first half of 2027 and expects initial data in the second half of 2027.
